Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A 300357
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CN¥18.87
- Day Range
- CN¥18.48–19.45
- 52-Week Range
- CN¥18.48–35.84
- Bid/Ask
- CN¥19.39 / CN¥19.40
- Shares Outstanding
- 523.58M
- Market Cap
- CN¥10.15B
- Volume/Avg
- 6M / 10M
Key Statistics
- Price/Earnings (Normalized)
- 24.43
- Price/Sales
- 9.29
- Dividend Yield (Trailing)
- 1.29%
- Dividend Yield (Forward)
- 1.29%
- Dividend Payment Schedule
- Jan, Jul
- Total Yield
- 1.29%
Company Profile
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is engaged in Research, development, production and sales of biopharmaceutical products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,808
- Website
- https://www.wolwobiotech.com
Valuation
|
Metric
|
300357
|
|---|---|
Price/Earnings (Normalized) | 24.43 |
Price/Book Value | 3.69 |
Price/Sales | 9.29 |
Price/Cash Flow | 23.17 |
Price/Earnings
300357
Financial Strength
|
Metric
|
300357
|
|---|---|
Quick Ratio | 10.53 |
Current Ratio | 12.11 |
Interest Coverage | 599.67 |
Quick Ratio
300357
Profitability
|
Metric
|
300357
|
|---|---|
Return on Assets (Normalized) | 13.13% |
Return on Equity (Normalized) | 14.42% |
Return on Invested Capital (Normalized) | 13.46% |
Return on Assets
300357
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|KYNwSV$ | LOCK|Sj | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|&lXys&M | LOCK|<># | $635B | |||
| AbbVie Inc
ABBV
| LOCK|kphbf%s | LOCK|Zf | $505B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|SXMbRhvh | LOCK|>@& | $381B | |||
| Merck & Co Inc
MRK
| LOCK|zV&V&HR | LOCK|m# | $358B | |||
| Novartis AG ADR
NVS
| LOCK|J<qr^@Q? | LOCK|B>% | $297B | |||
| AstraZeneca PLC
AZN
| LOCK|f&!S%<!z | LOCK|VFd | $267B | |||
| Amgen Inc
AMGN
| LOCK|%@nH!&D | LOCK|N< | $237B | |||
| Gilead Sciences Inc
GILD
| LOCK|QL^&GF@ | LOCK|R#F | $193B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Hqflnh% | LOCK|!%T | $172B |
United States